Angioedemas, Hereditary clinical trials

The registry lists 171 studies for Angioedemas, Hereditary across more than 10 countries. 24 are recruiting or about to start. 160 of them are mainly about Angioedemas, Hereditary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Angioedemas, Hereditary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 114
Recruiting: 13
Active, not recruiting: 11
Terminated: 9
Withdrawn: 5
Enrolling by invitation: 5

Phase

Phase 3: 60
Phase 2: 35
Phase 1: 22
Phase 4: 10
Early Phase 1: 1

Where

United States: 84
Germany: 60
United Kingdom: 51
Canada: 48
Italy: 43
France: 38

Who runs them

Shire (39) · Takeda (19) · BioCryst Pharmaceuticals (17) · KalVista Pharmaceuticals, Ltd. (12) · CSL Behring (11) · Pharvaris Netherlands B.V. (8) · Pharming Technologies B.V. (8) · Ionis Pharmaceuticals, Inc. (6)

What is being tested here

Drugs under test in Angioedemas, Hereditary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Deucrictibant	4	4	5
Onvuzosiran sodium	2	2	3
Berotralstat	1	5	11
C1 esterase inhibitor (human)	1	2	11
Sebetralstat	1	4	7
Navenibart	1	2	5
Donidalorsen	1	3	5
Complement C1 Inhibitor Protein	0	10	17
Icatibant	0	7	10
Lanadelumab	0	6	8

Coming up

12phase 3 studies under way

10studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Dec 2026A Study of Navenibart in Participants With Hereditary Angioedema · Phase 3 · Astria Therapeutics, Inc.
Dec 2026A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) · Phase 3 · Ionis Pharmaceuticals, Inc.
Jun 2027Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema · Phase 3 · Pharvaris Netherlands B.V.
Jun 2027Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency · Phase 3 · Pharvaris Netherlands B.V.
Nov 2027STOP-HAE: A Phase 3 Study of ADX-324 in HAE · Phase 3 · ADARx Pharmaceuticals, Inc.
Dec 2026A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) · Takeda
Feb 2027Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · Istituti Clinici Scientifici Maugeri SpA
Jun 2027A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · Takeda
Jul 2027Angioedema Biomarker Research Study · Foundation For Rare Disease Research
Nov 2027Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) · KalVista Pharmaceuticals, Ltd.

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger. 7 (54%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.

Recruiting studies that take each age, of 13
Age	Women	Men
10	2 (15%)	2 (15%)
18	12 (92%)	12 (92%)
30	12 (92%)	12 (92%)
40	12 (92%)	12 (92%)
50	12 (92%)	12 (92%)
65	12 (92%)	12 (92%)
75	12 (92%)	12 (92%)
85	9 (69%)	9 (69%)

Across all 171 studies, recruiting or not: 33% stop at 75 or younger and 27% at 65; 60% take children; 0% are for women only and 3% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Angioedemas, Hereditary studies take

Of 46 phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	5 mo4–9 · 13 studies	—	—
Phase 2	19 mo11–35 · 17 studies	—	—
Phase 3	22 mo16–33 · 46 studies	22 mo16–33 · 46 studies	—
Observational	43 mo36–56 · 27 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South KoreaOct 15, 2026NCT07445087

Studies

Recruiting first, then most recently updated. Showing 50 of 171. Browse all 171 → or search them.